Literature DB >> 9144515

Mitogen-activated protein kinase activation during IgG-dependent phagocytosis in human neutrophils: inhibition by ceramide.

S J Suchard1, P J Mansfield, L A Boxer, J A Shayman.   

Abstract

In FMLP-activated polymorphonuclear leukocytes (PMNs) challenged with IgG-opsonized erythrocytes (EIgG), the termination of phagocytosis correlates with an accumulation of ceramide, a product of sphingolipid metabolism. Furthermore, the exogenous addition of short chain ceramides inhibits EIgG-mediated phagocytosis. In the present study, we identified p42 and p44 mitogen-actived protein (MAP) kinases, referred to as extracellular signal-regulated kinases ERK2 and ERK1, respectively, as intracellular targets of ceramide action during Fc gammaR-mediated phagocytosis. The tyrosine phosphorylation of ERK1 and ERK2 increased within 30 s of addition of EIgG, with maximal phosphorylation by 1 to 5 min. By 30 min, ERK1 and ERK2 were almost completely dephosphorylated. The kinetics of ERK1 and ERK2 tyrosine phosphorylation indicated that MAP kinase activation preceded target ingestion. N-Acetylsphingosine (C2-ceramide) inhibited phagocytosis, reduced ERK1 and ERK2 phosphorylation to basal levels, and reduced ERK1 and ERK2 activity by 85 to 90% and 70 to 80%, respectively. In contrast, N-acetyldihydrosphingosine (dihydro-C2-ceramide) had no effect on either tyrosine phosphorylation or activity of ERK1 and ERK2. In the presence of the MAP kinase kinase (MEK) inhibitor, PD 098059, phagocytosis was reduced by approximately 50%, while ERK1 and ERK2 activity was reduced by 85 to 90%. Thus, engagement of Fc gammaRs led to ERK1 and ERK2 phosphorylation and activation, and the activation of these enzymes was critical for phagocytosis. Furthermore, the inhibition of phagocytosis by C2-ceramide correlated with the inhibition of tyrosine phosphorylation and activation of ERK1 and ERK2. These results suggest that ceramides generated during phagocytosis act on the MAP kinase signaling pathway, ultimately "turning off" the phagocytic response.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144515

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Mitogen-activated protein kinase is activated during IgG-mediated phagocytosis, but is not required for target ingestion.

Authors:  K Karimi; M R Lennartz
Journal:  Inflammation       Date:  1998-02       Impact factor: 4.092

2.  Listeria monocytogenes invasion of epithelial cells requires the MEK-1/ERK-2 mitogen-activated protein kinase pathway.

Authors:  P Tang; C L Sutherland; M R Gold; B B Finlay
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

3.  An obligate role for membrane-associated neutral sphingomyelinase activity in orienting chemotactic migration of human neutrophils.

Authors:  Robert G Sitrin; Timothy M Sassanella; Howard R Petty
Journal:  Am J Respir Cell Mol Biol       Date:  2010-04-08       Impact factor: 6.914

Review 4.  Sphingolipids in neutrophil function and inflammatory responses: Mechanisms and implications for intestinal immunity and inflammation in ulcerative colitis.

Authors:  Mel Pilar Espaillat; Richard R Kew; Lina M Obeid
Journal:  Adv Biol Regul       Date:  2016-11-14

5.  Role of the extracellular signal-regulated protein kinase cascade in human neutrophil killing of Staphylococcus aureus and Candida albicans and in migration.

Authors:  C S Hii; K Stacey; N Moghaddami; A W Murray; A Ferrante
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

6.  CB2 receptor activation inhibits the phagocytic function of microglia through activating ERK/AKT-Nurr1 signal pathways.

Authors:  Qi-Wen Han; Qian-Hang Shao; Xiao-Tong Wang; Kai-Li Ma; Nai-Hong Chen; Yu-He Yuan
Journal:  Acta Pharmacol Sin       Date:  2022-02-07       Impact factor: 7.169

Review 7.  Signal transduction of stress via ceramide.

Authors:  S Mathias; L A Peña; R N Kolesnick
Journal:  Biochem J       Date:  1998-11-01       Impact factor: 3.857

8.  Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide.

Authors:  Yan Sun; Todd Fox; Gautam Adhikary; Mark Kester; Eric Pearlman
Journal:  J Leukoc Biol       Date:  2008-04-17       Impact factor: 4.962

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.